look ahead report
wedbush view biotech sector lag broader market
ytd nbi vs revisit setup commerci
coverag includ outperform-r neutral-
rate dova among cover name look continu
commerci execut despit zulresso launch
kickoff investor focus upcom mountain
readout lower target
amidst recent sector multipl compress target
also drop target fall chang outlook
outperform new target look continu execut
soliris/ultomiri rais franchis estim follow recent kol dinner
manag acceler ultomiri convers guidanc
rais soliris/ultomiri revenu estim
vs company-sponsor consensu off-set lower
strensiq revenu estim net impact chang plu lower
earn multipl vs bring target
outperform new target ahead addit catalyst anticip
in-lin quarter manag note updat data like
nda submiss complet august look formal
accept applic well clariti prioriti review chang
product revenu estim adjust cash project
target move remain outperform rate
outperform target eye mountain top-lin data
zulresso launch kick materi uptak still like quarter
estim remain unchang target continu
hold posit bia readout anticip remain
neutral new target anticip pressur ms franchis
rais tecfidera spinraza revenu estim
respect remain behind consensu estim
recent sector multipl compress appli
new valuat multipl previous deriv target
move
dova neutral target ahead acquisit report larg
non-ev amidst doptelet price reset nascent itp launch
anticip unlik see much benefit label expans
later quarter like impact propos sobi acquisit
chang thing project close anticip
report unlik impact share
neutral new target littl light end tunnel lower
target manag recent note increas cover live inbrija
script data show limit growth dollar averag weekli growth
august continu model below-consensu estim chang
estim lower discount rate drop target previous
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
wedbush view ahead biotech financi report revisit setup
commerci coverag includ outperform-r neutral-
rate dova among cover name look continu commerci
execut despit zulresso launch kickoff investor
focus upcom mountain readout lower target
amidst recent sector multipl
compress target also drop target fall
chang outlook
note bmo market open market close tbd determin
perform lag despit solid fundament
overal biotech sector perform remain lacklust compar vertic nbi
post ytd versu see figur look close subsector
within healthcar group note biotech perform lag subsector
includ healthcar technolog ytd healthcar equip supplier
ytd theme weigh sector past sever month includ weak across
equiti market well concern surround potenti policy/regulatori chang
affect sector
note price qtd quarter date ytd year date
look ahead think overal biotech sector fundament appear solid notabl
valuat across large-cap mid-cap group remain attract large-cap biotech
trade discount earn multipl rel broader market see figur
note price
addit smid-cap acquisit also pick past sever month includ
announc sobi acquisit dova ucb propos acquisit rarx
serv remind ever-pres theme biotech large-cap biotech/pharma
continu need de-risk mid-/late-stag asset think dynam bode well
compani fit framework among name within coverag point
outperform-r one exampl
beyond valuat access capit remain strong evidenc continu ipo
reach public market ipo tracker estim total biotech ipo
complet ipo innat pharma come later month figur
summar deal activ averag sinc ipo transact per
year rais annual date sector seen rais via ipo
see posit dynam sector overal gaug investor sentiment
toward biotech space note polit concern continu pressur
sector may well increas fundrais timelin near term particularli
us elect escal drug price rhetor like receiv increas
herein review company-specif outlook six commercial-stag compani within
coverag univers dova
outperform new target ahead anoth potenti ultomiri approv look
continu execut report financi result market
open figur depict current estim rel current consensu
estim describ detail herein continu hold posit bia
execut date look continu strength complement franchis
soliris/ultomiri recent kol event provid outsid perspect convers
process one us-bas institut appear go well recent commentari
manag depict strong us-bas launch ultomiri pnh
potenti approv ahu see anoth growth driver soon follow specif
model combin soliris/ultomiri revenu ahead consensu vs
note product consensu obtain company-sponsor consensu total revenu ep estim
thomson reuter complement franchis estim company-sponsor consensu
make sever minor adjust estim first trim
strensiq revenu trajectori ex-u region kanuma revenu
estim remain unchang thu overal metabol franchis estim slightli behind
consensu vs shown
second revisit soliris/ultomiri franchis estim assumpt although
manag previous note headwind financi result canadian
soliri price fx headwind impact full year recent
commentari indic ultomiri convers progress septemb manag
note soliri patient transit ultomiri addit compani pull
forward time guidanc convert market pnh remain
ultra-rar condit envis ultomiri potenti increas address market
popul due less frequent dose increas assumpt
surround proport patient treat us eu region increas
market share assumpt region well deriv soliris/ultomiri combin
revenu ahead manag guid rang current consensu
figur summar current financi guidanc provid last earn
report note estim pre-exist consensu total revenu
ahead guid rang see
figur current guidanc report
note alexion financi guidanc base current foreign exchang rate net hedg activ
includ effect acquisit licens collabor agreement intang asset
impair litig charg chang fair valu conting consider restructur
relat activ outsid previous announc activ may occur issuanc
present reconcili non- financi guidanc provid appendix
avail www alexion com yoy growth use mid-point guidanc rang
amidst recent sector multipl compress revisit valuat methodolog
incorpor aforement estim chang appli earn
multipl previous ep estim discount back per year
deriv new target previous large-cap biotech peer trade mean
earn multipl consensu earn given current sector sentiment
alxn platform view appropri multipl pleas see detail
view valuat incom statement risk clinical/regulatori commerci
outperform target head mountain financi report like offer
limit impact report financi result market open
zulresso launch earli stage manag emphas limit traction earli
stage compani work refin suppli chain get facil rem
certif process begin refin payer/reimburs framework mind
keep zulresso estim unchang stage think financi
result unlik provid meaning move stock investor remain focus
upcom mountain pivot readout tabl illustr
current estim rel consensu valu
note product consensu obtain bloomberg total revenu ep estim thomson reuter
recent manag commentari note approxim rem-
certifi site prepar zulresso administr goal site manag continu
anticip take sever quarter refin logist zulresso revenu acceler
manag provid guidanc surround zulresso product revenu stage
guid cash runway expect cash end year
sector come pressur last three month nbi share
pull back meaning updat continu hold posit outlook
name upcom mountain readout base consist chang
depress reduct seen across previou studi risk clinical/regulatori
outperform new target clariti faod file continu gain crysvita
report financi result estim overal remain unchang
head report outsid financi result anticip near-term clariti
accept nda submiss rare end also would look clariti
around prioriti review potenti advisori committe meet tabl
illustr current estim rel consensu valu
note product consensu obtain bloomberg total revenu ep estim thomson reuter
await addit updat program well valuat
methodolog remain unchang laps partial discount period adjust
cash/bal sheet project sum-of-part dcf analysi deriv target
previous base project cash flow crysvita mepsevii
discount back per year appropri discount rate base compani
earli commerci stage develop continu hold outperform rate
share see compani orphan focus pipelin one broadest
dova neutral target non-ev best dova formal schedul earn
date howev base prior histori anticip releas sobi
acquisit set close upcom earn report hold much less suspens
recal doptelet approv itp indic late-jun commerci launch
commenc mid-juli coupl price reset doptelet believ
print inform regard potenti impact itp label
updat tabl summar current dova estim rel current consensu
note product consensu obtain bloomberg total revenu ep estim thomson reuter
stay consist valuat methodolog use sum-of-part dcf analysi
target remain unchang overal continu hold posit outlook
dova doptelet share current trade near acquisit price see
balanc risk/reward stage remain neutral rate dova share risk
neutral new target anticip mix report report financi
result bmo overal make minor adjust estim
assum mix updat follow beat first increas sg
expens trajectori remaind better tie guidanc model
 sg expens respect repres approxim
revenu line item within guid rang
second increas tecfidera estim us continu remain
consensu see figur third increas spinraza estim also
remain consensu net chang yield total revenu
total revenu estim impli chang versu report total revenu
note product consensu obtain bloomberg total revenu ep estim thomson reuter
standard practic manag provid financi guidanc updat
begin year mid-year updat slide provid current
financi guidanc framework updat
note capit expenditur previous anticip rang
recal manag highlight nine late stage readout gosuranemab
result phase passport studi psp expect near term although
phase psp data potenti pivot support regulatori file
inclin studi unlik read favor even result posit
stock unlik realiz meaning boost see psp preview
backdrop recent multipl compress space lower valuat
earn multipl large-cap biotech peer trade
multipl consensu earn discount peer group appear warrant base
recent pipelin setback litig involv tecfidera exclus layer model
updat stay consist methodolog examin price-to-earnings multipl
ep estim discount back per year price target move
previous continu hold neutral rate share risk
neutral new target light end tunnel yet report
financi result market close recal manag previous guid
ampyra revenu exceed financi report recent script trend data
suggest continu declin ampyra prescrib would expect amidst entri
gener competitor ampyra revenu estim remain unchang point
continu model ampyra revenu consensu
inbrija see littl chang prescrib trajectori current script trend data
note manag recent updat inbrija avail without medic except
commerci live medicar live compar
respect updat manag implement patient assist program
sampl may interfer true uptak visibl script data thu caveat
script data may provid incomplet pictur see figur
first figur blue bar correspond inbrija trx dollar week orang line
repres weekli prescrib count focus trx dollar week note level
appear larg plateau past two month averag w/w chang
sinc august second figur compar weekli count project number prescript
dispens versu weekli prescrib count number uniqu prescrib wrote least
one prescript week wrx latter figur prescrib begin expand
usag drug would look see count increas use patient
howev sinc august averag w/w wrx count increas similar chang
count maintain below-consensu inbrija estim vs
await materi sign inflect revenu trajectori
note week end holiday week memori day independ day
figur illustr current product revenu estim well total revenu
note product consensu obtain bloomberg total revenu ep estim thomson reuter
outsid ampyra revenu guidanc manag provid inbrija revenu
guidanc initi product launch beyond revenu expens guidanc
compani follow
non-gaap expens
non-gaap sg expens
make chang product revenu assumpt updat balanc
sheet project increas discount rate yield new target
share previous increas discount risk reflect risk associ
launch limit catalyst line-up ahead pleas see full descript sum-
of-part valuat incom statement risk clinical/regulatori commerci competit
risk attain price rate biotechnolog
risk achiev price target includ advers polit event better worse-than expect clinic data
under-perform outperform rate respect
laura chico certifi view express report accur reflect person opinion
directli indirectli receiv compens payment connect specif recommend view contain
report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
octob
octob
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
